Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
Document Type
Journal Article
Publication Date
9-1-2015
Journal
Pediatric Blood and Cancer
Volume
62
Issue
9
Inclusive Pages
1562-1566
DOI
10.1002/pbc.25548
Keywords
Angiogenesis Inhibitors--therapeutic use; Antineoplastic Agents--therapeutic use; Kidney Neoplasms--drug therapy; Niacinamide--analogs & derivatives; Phenylurea Compounds--therapeutic use; Protein Kinase Inhibitors--therapeutic use; Rhabdomyosarcoma--drug therapy; Salvage Therapy; Wilms Tumor--drug therapy
APA Citation
Kim, A., Widemann, B. C., Krailo, M., Jayaprakash, N., Fox, E., Weigel, B., & Blaney, S. M. (2015). Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the children's oncology group. Pediatric Blood and Cancer, 62(9), 1562-1566.
Peer Reviewed
1
COinS